NCT04910633

Brief Summary

An article to present how cancer patients were taken in charge at Lyon University Hospital Cancer Institute (France) during the first peak of the COVID-19 pandemic between March and May 2020 is under writing. It will present strategies that were set-up to avoid cross-contamination between patients and caregivers, patients treatment adaptation (timing, dosage,..) and how consultations, multidisciplinary team meetings, surgical procedures and clinical trials were impacted. Part of this article will also illustrate the characteristics of patients with a solid tumor(s) that have been hospitalized during this timeframe for the COVID-19. How cancer type and stage affect Covid severity and mortality.will be described for a small sample of patients (44). These qualitative figures will be compared to literature current state of the art.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 2, 2020

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 9, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 22, 2021

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 10, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

June 2, 2021

Completed
Last Updated

June 2, 2021

Status Verified

May 1, 2021

Enrollment Period

7 days

First QC Date

May 10, 2021

Last Update Submit

June 1, 2021

Conditions

Keywords

COVID-19CancerSolid TumorQualitative studyFirst pandemic wave

Outcome Measures

Primary Outcomes (1)

  • Illustration of the repartition of COVID+ patient severity (Low/Medium/Severe status) depending on cancer nature, stage and patient age.

    COVID-19 severity will be determined based on chest X-Ray damage as follow. Low severity : ≤25% of chest X-Ray damage, Middle severity: between 25-50% of chest X-Ray damage, High Severity : above 50% of chest X-Ray damage. A graphic will then be drafted to present the relationship between Covid-19 severity depending on patient age, cancer nature, and cancer stage.

    At the end of Month 1

Study Arms (1)

Solid Tumor and COVID-19

Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.

Other: COCA is an observational study based on retrospective data issued from patient medial file.

Interventions

The following parameters will be collected from the medical files of the patients involved in this study: * Age * Gender * Cancer type * Cancer Stage * Cancer Treatment * COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%) * Living Status * Attribution of Mortality to COVID status * Comorbidities

Solid Tumor and COVID-19

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a LUHCI cancer code created after 2015 and a LUHCI COVID-19 code created between March 2020 and May 2020.

You may qualify if:

  • Patients with a LUHCI code created after 2015 and a LUHCI COVID-19 code created between March 2020 and May 2020.

You may not qualify if:

  • Patients who did not allow the reuse of their medical file data for research related to COVID-19-

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lyon University Hospital Cancer Institute

Bron, 69 677, France

Location

MeSH Terms

Conditions

NeoplasmsCOVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 10, 2021

First Posted

June 2, 2021

Study Start

December 2, 2020

Primary Completion

December 9, 2020

Study Completion

January 22, 2021

Last Updated

June 2, 2021

Record last verified: 2021-05

Locations